(UroToday.com) Dr. Giorgio Gandaglia discussed the identification of the best candidates for PSMA PET/CT among those experiencing a biochemical recurrence after radical prostatectomy at the European Association of Urology (EAU) 2021 annual meeting’s detection of recurrence and salvage treatment options after primary treatment of prostate cancer session. Although PSMA PET/CT is recommended in the biochemical recurrence setting after radical prostatectomy, its impact on clinical management is unclear. This is particularly true when considering prostate cancer patients at low risk of metastases who could be managed with salvage radiotherapy alone. The objective of this study was to assess when PSMA PET/CT could be safely avoided or postponed.